Immune therapy scores big win against lung cancer in study
In the study, Merck’s Keytruda, given with standard chemotherapy, cut in half the risk of dying or having the cancer worsen, compared to chemo alone after nearly one year.
Related articles
-
Trump loyalist Kash Patel questioned before Mar-a-Lago grand jury
November 4, 2022 -
The House Republican ‘no’ caucus is at it again
April 6, 2022 -
Man City need more than Haaland as season sits on knife's edge
November 27, 2024
